Clinical Trial

Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 18, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Based on the current treatment with retinoic acid (ATRA) and arsenic (As), most patients with APL achieved long-term survival. There are few patients relapsed and became refractory to the RA and As treatment. In our pre-clinical study, we found that targeting histone deacetylase inhibitor 3 (HDAC3)degraded PML-RARa oncoprotein and induced differentiation and apoptosis of RA and As resistant APL in vitro and in vivo. In this study, we evaluate the efficacy and feasibility of combination therapy for HDAC3 inhibitor and venetoclax in patients with refractory APL.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-05-30; most recent amendment 2025-02-14.
Status change: Active, Not Recruiting → Recruiting 2023-08-10
Trial Details
NCT Number NCT05881265
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Collaborators: Shanghai Clinical Research Center
Conditions APL
Enrollment 30 participants
Start Date 2023-05-15
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-18